Hybrid cell line for producing monoclonal antibody to antigen on human thymocytes
AssigneeOrtho Pharmaceutical Corporation
InventorsPatrick C. Kung, Gideon Goldstein
Life of this patent
Estimating the term…
Abstract
Hybrid cell line for production of monoclonal antibody to an antigen found on approximately 95% of normal human thymocytes. The hybrid is formed by fusing splenocytes from immunized CAF.sub.1 mice with P3X63Ag8U1 myeloma cells. Diagnostic and therapeutic uses of the monoclonal antibody are also disclosed.
Claims6
A hybridoma having the identifying characteristics of TCC CRL 8022.
A hybridoma capable of producing mouse monoclonal antibody that reacts with an antigen found on approximately ninety-five percent (95%) of normal human thymocytes and five percent (5%) of normal human peripheral T Cells.
A hybridoma capable of producing mouse monoclonal antibody that reacts with an antigen found on approximately 95% of normal human thymocytes and on leukemic T-ALL cells.
A hybridoma formed by fusion of cells from a mouse myeloma line and spleen cells from a mouse previously immunized with human leukemic T-ALL cells, which is capable of producing monoclonal antibody that:
- reacts with approximately 95% of normal human thymocytes, 5% of normal human peripheral T cells, 10% of E.sup.- peripheral mononuclear cells (B cells and null cells), and 10-20% of bone marrow cells.
Dependencies are inferred from the claim text.